These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28624872)

  • 1. Abaloparatide: First Global Approval.
    Shirley M
    Drugs; 2017 Aug; 77(12):1363-1368. PubMed ID: 28624872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abaloparatide for the treatment of postmenopausal osteoporosis.
    Pietrogrande L; Raimondo E
    Drugs Today (Barc); 2018 May; 54(5):293-303. PubMed ID: 29911694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.
    Bilezikian JP; Hattersley G; Fitzpatrick LA; Harris AG; Shevroja E; Banks K; Leder BZ; Zanchetta JR; Hans D
    Osteoporos Int; 2018 Feb; 29(2):323-328. PubMed ID: 29167971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
    Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
    J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.
    Watts NB; Hattersley G; Fitzpatrick LA; Wang Y; Williams GC; Miller PD; Cosman F
    Osteoporos Int; 2019 Jun; 30(6):1187-1194. PubMed ID: 30899994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
    McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
    Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density.
    Miller PD; Troy S; Weiss RJ; Annett M; Schense J; Williams SA; Mitlak B
    Clin Drug Investig; 2021 Mar; 41(3):277-285. PubMed ID: 33638863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis.
    Miller PD; Bilezikian JP; Fitzpatrick LA; Mitlak B; McCloskey EV; Cosman F; Bone HG
    Curr Med Res Opin; 2020 Nov; 36(11):1861-1872. PubMed ID: 32969719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis.
    Merlotti D; Falchetti A; Chiodini I; Gennari L
    Expert Opin Pharmacother; 2019 May; 20(7):805-811. PubMed ID: 30856013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis.
    McClung MR; Harvey NC; Fitzpatrick LA; Miller PD; Hattersley G; Wang Y; Cosman F
    Menopause; 2018 Jul; 25(7):767-771. PubMed ID: 29462094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture.
    Saag KG; Williams SA; Wang Y; Weiss RJ; Cauley JA
    Clin Ther; 2020 Jun; 42(6):1099-1107.e1. PubMed ID: 32513495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
    Leder BZ; Mitlak B; Hu MY; Hattersley G; Bockman RS
    J Clin Endocrinol Metab; 2020 Mar; 105(3):938-43. PubMed ID: 31674644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abaloparatide: A new pharmacological option for osteoporosis.
    Sleeman A; Clements JN
    Am J Health Syst Pharm; 2019 Jan; 76(3):130-135. PubMed ID: 30689744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis.
    Reginster J-; Bianic F; Campbell R; Martin M; Williams SA; Fitzpatrick LA
    Osteoporos Int; 2019 Jul; 30(7):1465-1473. PubMed ID: 30953114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
    Cosman F; Miller PD; Williams GC; Hattersley G; Hu MY; Valter I; Fitzpatrick LA; Riis BJ; Christiansen C; Bilezikian JP; Black D
    Mayo Clin Proc; 2017 Feb; 92(2):200-210. PubMed ID: 28160873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide.
    Reginster JY; Hattersley G; Williams GC; Hu MY; Fitzpatrick LA; Lewiecki EM
    Calcif Tissue Int; 2018 Nov; 103(5):540-545. PubMed ID: 29951742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abaloparatide (Tymlos) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2017 Jun; 59(1523):97-98. PubMed ID: 28609423
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis.
    Sheth NP; Smith JR; Winzenrieth R; Humbert L; Wang Y; Boxberger JI; Bostrom MP
    J Bone Joint Surg Am; 2024 Jul; 106(13):1162-1170. PubMed ID: 38691582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors.
    Cosman F; Hattersley G; Hu MY; Williams GC; Fitzpatrick LA; Black DM
    J Bone Miner Res; 2017 Jan; 32(1):17-23. PubMed ID: 27612281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.